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Abstract Genetic variation of antigen-processing machinery
(APM) components has been shown to be associated with
cervical carcinoma risk and outcome in a genetically homo-
geneous Dutch population. However, the role of APM com-
ponent single nucleotide polymorphisms (SNPs) in genetical-
ly heterogeneous populations with different distributions of
human papillomavirus (HPV) subtypes remains unclear. Elev-
en non-synonymous, coding SNPs in the TAP1, TAP2, LMP2,
LMP7 and ERAP1 genes were genotyped in cervical carcino-
ma patients and healthy controls from two distinct Indonesian
populations (Balinese and Javanese). Individual genotype and
allele distributions were investigated using single-marker
analysis, and combined SNP effects were assessed by haplo-
type construction and haplotype interaction analysis. Allele
distribution patterns in Bali and Java differed in relation to
cervical carcinoma risk, with four ERAP1 SNPs and one
TAP2 SNP in the Javanese population showing significant
association with cervical carcinoma risk, while in the Balinese
population, only one TAP2 SNP showed this association.
Multimarker analysis demonstrated that in the Javanese pa-
tients, one specific haplotype, consisting of the ERAP1-575
locus on chromosome 5 and the TAP2-379 and TAP2-651 loci
on chromosome 6, was significantly associated with cervical
carcinoma risk (global P=0.008); no significant haplotype
associations were found in the Balinese population. These
data indicate not only that genetic variation in APM compo-
nent genes is associated with cervical carcinoma risk in Indo-
nesia but also that the patterns of association differ depending
on background genetic composition and possibly on differ-
ences in HPV type distribution.
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Introduction
The antigen-processing machinery (APM) comprises various
components working together to determine the presentation of
peptides derived from intracellular proteins by human leuco-
cyte antigen (HLA) class I molecules (Heemels and Ploegh
1995). The APM has been shown to be important in immune
recognition of virally infected cells and tumour cells. Defects
in the APM have been shown to be associated with progres-
sion and impaired survival in various tumours (Facoetti et al.
2005; Meissner et al. 2005; Seliger et al. 2006). In particular,
we have shown previously that downregulation of endoplas-
mic reticulum aminopeptidase associated with antigen presen-
tation 1 (ERAP1), transporter associated with antigen
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presentation 1 (TAP1) and low molecular weight peptide 7
(LMP7) is significantly associated with decreased survival in
human papilloma virus (HPV) associated cervical carcinoma
(Mehta et al. 2008).
Apart from APM protein expression defects, we have pre-
viously hypothesized that genetic variation in the genes
encoding APM components may contribute to susceptibility
to cervical carcinoma. We have demonstrated that various
single nucleotide polymorphisms (SNPs) in the LMP7, TAP2
and ERAP1 genes were significantly associated with risk of
developing cervical carcinoma in the Dutch population
(Mehta et al. 2007). Moreover, two ERAP1 SNPs were found
to be significantly associated with poor survival in Dutch cer-
vical cancer patients (Mehta et al. 2009).
Although these data suggest that genetic variation in APM
genes is an important determinant in the development and
progression of cervical carcinoma in the Dutch population, it
remains to be determined whether these findings can be ex-
trapolated to other gene pools and populations. Our group has
previously shown that the distribution of HPV subtypes
among cervical carcinoma patients in Indonesia, where high
incidence of HPV infection has been recorded, differs from
other geographical areas (Vet et al. 2008). This was hypothe-
sized to be caused by the relative isolation of certain Indone-
sian regions and subpopulations.
To ascertain the extent to which APM genetic variation
may contribute to cervical carcinoma risk in regions in which
HPV is virtually endemic, we have studied the genotypes and
genotype interactions of a previously reported set of SNPs in
distinct Indonesian populations from Java and Bali. We dem-
onstrate that, as in the Dutch population, APM genetic varia-
tion is associated with cervical carcinoma risk but that the




Cervical cancer cases and healthy controls were derived from
two distinct Indonesian populations from Java and Bali. In the
Javanese population, cervical carcinoma cases consisted of 98
female patients with histologically confirmed invasive cervi-
cal cancer from the regions of Jakarta and Tasikmalaya, while
105 healthy female controls from the same area were included
in the study. In the Balinese population, 103 cervical carcino-
ma patients and 68 healthy controls were included.
HPV typing was performed by using the SPF10 primer set
and INNO-LIPA HPV Genotyping Extra line probe assay
(Fujirebio Europe, Ghent, Belgium). In 87 (89 %) of the Ja-
vanese patients, high-risk HPV was detected: The most com-
mon types were HPV16 (n=35; 35.7 %), HPV18 (n=28;
28.6 %) and HPV52 (n=15; 15.3 %). In 77 (74.8 %) of the
103 Balinese patients, high-risk HVwas detected, of whom 38
(36.9 %) were HPV16 positive, 16 (15.5 %) were HPV18
positive and 8 (7.8 %) were HPV52 positive.
DNA isolation from cervical swabs was performed by
Baseclear (Leiden, the Netherlands) using a magnetic bead-
based assay. DNA was extracted from formalin-fixed,
paraffin-embedded cervical tumour tissue using the Tissue
Preparation System (Siemens Healthcare Diagnostics, NY,
USA) (Hennig et al. 2010).
SNP genotyping
Eleven previously documented polymorphisms in the LMP2,
LMP7, TAP1, TAP2 (chromosome 6) and ERAP1 (chromo-
some 5) coding regions were genotyped using TaqMan SNP
Genotyping Assays (Applied Biosystems, Inc., Foster City,
CA) based on the 5′-nuclease allelic discrimination assay as
described previously (Livak 1999). A combination of pre-
designed assays (available as Assays-on-Demand products)
and custom SNP Genotyping Assays (available through the
Assays-by-Design service) was used. Probe and primer se-
quences for the Custom SNP Genotyping Assays and avail-
able information for the pre-designed SNP Genotyping As-
says have been described previously (Mehta et al. 2007).
SNP genotyping was performed as described previously
(Mehta et al. 2007). In short, real-time PCR was performed
in a 5 ul reaction volume containing 10 ng of patient or control
genomic DNA (dried by overnight evaporation), 1× final con-
centration of TaqMan Universal PCR Mix and 1× final con-
centration of the appropriate TaqMan SNP Genotyping Assay
(0.9 umol/l of each primer and 0.2 umol/l of each probe). All
liquid handling was performed with a Genesis RSP 100 auto-
mated liquid pipetting system (Tecan Group Ltd., Männedorf,
Switzerland). PCR reactions were carried out and read in an
ABI PRISM 7900HT sequence detection system (Applied
Biosystems) with the following cycling conditions: 95 °C
for 10 min, followed by 40 cycles of 92 °C for 15 s and
60 °C for 1 min. Data acquisition and allelic discrimination
were performed using Sequence Detection Systems software
version 2.2.2 (Applied Biosystems).
Statistical analysis
For each polymorphism, deviation of the genotype frequen-
cies from those expected under Hardy-Weinberg equilibrium
was assessed using chi-squared tests implemented in
Haploview software version 3.2 (Barrett et al. 2005). Distri-
bution of possible genotypes at the investigated SNP loci was
compared among cases and controls using the chi-squared
test. The Armitage trend test, as implemented in FAMHAP
software version 19, was used to test for a trend in cervical
carcinoma risk with individual allele numbers (Sasieni 1997).
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Chromosome 5 and 6 haplotypes were constructed, haplo-
type frequencies were estimated, and haplotype interaction
analysis of the two chromosomes was performed using the
expectation-maximization (EM) algorithm implemented in
FAMHAP software version 19 (Becker et al. 2005a, b; Becker
and Knapp 2004; Mehta et al. 2007). Miettinen’s formula was
used to calculate the population attributable fraction (PAF),
i.e. the fraction of all cervical carcinoma cases attributable to
a haplotype observed to be significantly associated with dis-
ease (Hanley 2001; Miettinen 1974).
All tests were two-sided, and the significance level was set
to 0.05. Where appropriate, P values were corrected for mul-
tiple testing. Statistical analyses were performed with IBM
SPSS Statistics software version 20 (SPSS Inc., Chicago, IL).
Results
Genotype and allele distributions
Eleven previously reported non-synonymous polymorphisms
in the coding regions of LMP2, LMP7, TAP1, TAP2 and
ERAP1 were tested separately in the Javanese and Balinese
populations (Mehta et al. 2007, 2009). Major and minor al-
leles for the tested loci are shown in Table 1. In both popula-
tions, genotype distributions in cases and controls were in
Hardy-Weinberg equilibrium (data not shown). The results
of univariate analyses of the various genotype frequencies
among cases and controls, and the results of the Armitage
trend test, are shown in Tables 2 and 3 for the Javanese and
Balinese populations, respectively. As shown, in the Javanese
population, four ERAP1 SNPs and the TAP2-651 SNP were
significantly associated with cervical carcinoma occurrence,
whereas in the Balinese population, only the TAP2-651 locus
showed this association.
Single allele distributions were determined in both groups
to further evaluate the effect of individual major and minor
alleles at each of the 11 loci. As shown in Table 4, in the
Javanese population, allele distributions at the ERAP1-127,
ERAP1-528 and ERAP1-730 loci were significantly associat-
ed with altered cervical carcinoma risk (P=0.042, 0.032 and
0.031, respectively); presence of the minor allele at these loci
was associated with decreased cancer risk.
As shown in Table 5, in the Balinese population, only the
TAP2-651 locus was significantly associated with cervical
carcinoma risk, with the minor allele increasing this risk
(P<0.001).
Haplotype construction and frequency estimation
As our previous study demonstrated that genotype combina-
tions contribute to cervical carcinoma development to a larger
degree than individual SNPs, the effect of various SNP com-
binations spanning chromosomes 5 and 6 was assessed. To
this end, separate haplotypes were constructed spanning the
six ERAP1 SNPs on chromosome 5 and the five LMP2,
LMP7, TAP1 and TAP2 SNPs on chromosome 6. As there
was no obvious linkage disequilibrium among the SNPs in-
vestigated (data not shown), the EM algorithm was used to
estimate the most likely haplotype arrangements spanning all
loci (Becker et al. 2005a, b; Becker and Knapp 2004). Only
haplotypes with a frequency >1.0 % in controls were included
for further analysis.
As shown in Table 6, application of the EM algorithm on
the six SNPs in the ERAP1 gene region on chromosome 5
yielded eight common haplotypes with a frequency ≥1 % in
controls, representing >99 % of all possible haplotypes in the
Javanese population. For the five SNPs on chromosome 6,
nine common haplotypes were generated representing
>99% of all possible haplotypes in this population. As shown,
in the Javanese population, no significant global differences in
frequency distributions for the constructed haplotypes were
found among cases and controls.
For the Balinese population, six chromosome 5 and five
chromosome 6 haplotypes were generated with a frequency
≥1 % in controls, as shown in Table 7. Here too, no significant
global differences in frequency distributions for the constructed
haplotypes could be demonstrated among cases and controls.
As the perceived lack of association between the various
haplotypes and cancer risk may have resulted from the high
number of degrees of freedom in these distributions, permuta-
tional chi-squared testing was performed to identify specific
marker combinations along which haplotypes could be grouped,
thus limiting the number of degrees of freedom. This procedure
did not yield any statistically significant differences in distribu-
tion in the Balinese population for either chromosome 5 or 6.
Table 1 Single nucleotide polymorphism (SNP) sequence variation
SNP ID (dbSNP reference) Nucleotide variationa
ERAP1-56 (rs3734016) c.166G>A
ERAP1-127 (rs26653) c.380G>C









aGenbank accession numbers for reference sequences: NM_016442.2 for
ERAP1, NM_000593.5 for TAP1, NM_000544.3 for TAP2, NM_00280.4
for LMP2, and NM_148919.3 for LMP7
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However, in the Javanese population, grouping the chromo-
some 5 haplotypes according to ERAP1-575 and ERAP1-730
genotypes yielded a statistically significant difference in distri-
bution (P=0.014), as shown in Table 8. In particular, the com-
bination of a minor allele at ERAP1-575 and a major allele at
ERAP1-730 was most significantly associated with increased
cervical carcinoma risk, the PAF for this haplotype being
4.6 %, as calculated using Miettinen’s formula. Similarly,
grouping chromosome 6 haplotypes according to the
TAP2-379 and TAP2-651 genotypes led to a statistically
significant difference in distribution (P=0.042). Presence of
the major allele at both loci was most significantly associated
with increased cancer risk, with a PAF of 56.7 %.
Haplotype interaction analysis of chromosomes 5 and 6
Haplotype interaction analysis of both chromosome regions
was performed to assess the extent to which the chromosome
5 and 6 haplotype blocks may synergistically affect cervical
carcinoma risk.
Table 2 SNP genotype distributions in the Javanese population













ERAP1-56 85 (83.3) 3 (2.9) 14 (13.7) 73 (77.7) 1 (1.1) 20 (21.3) 0.266 0.224
ERAP1-127 25 (25.0) 49 (49.0) 26 (26.0) 34 (37.4) 41 (45.1) 16 (17.6) 0.132 0.047
ERAP1-276 39 (37.1) 51 (48.6) 15 (14.3) 31 (34.4) 40 (44.4) 19 (21.1) 0.456 0.348
ERAP1-528 25 (24.5) 49 (48.0) 28 (27.5) 32 (35.6) 43 (47.8) 15 (16.7) 0.108 0.036
ERAP1-575 100 (96.2) 4 (3.8) 0 (0.0) 84 (88.4) 11 (11.6) 0 (0.0) 0.119 0.039
ERAP1-730 26 (25.0) 53 (51.0) 25 (24.0) 35 (37.6) 44 (47.3) 14 (15.1) 0.097 0.031
TAP1-333 45 (44.1) 46 (45.1) 11 (10.8) 40 (46.0) 43 (49.4) 4 (4.6) 0.288 0.379
TAP2-379 44 (43.6) 44 (43.6) 13 (12.9) 48 (52.7) 34 (37.4) 9 (9.9) 0.435 0.215
TAP2-651 97 (93.3) 7 (6.7) 0 (0.0) 94 (98.9) 1 (1.1) 0 (0.0) 0.126 0.042
LMP2-60 55 (53.4) 42 (40.8) 6 (5.8) 47 (51.1) 40 (43.5) 5 (5.4) 0.929 0.824
LMP7-145 84 (81.6) 18 (17.5) 1 (1.0) 84 (90.3) 9 (9.7) 0 (0.0) 0.174 0.065
n (%) number (percentage)
All P values are corrected for multiple testing
Bold P values indicate statistical significance, i.e. P< 0.05
Table 3 SNP genotype distributions in the Balinese population













ERAP1-56 35 (85.4) 0 (0.0) 6 (14.6) 13 (72.2) 1 (5.6) 4 (22.2) 0.227 0.331
ERAP1-127 21 (33.9) 36 (8.1) 5 (8.1) 35 (35.4) 49 (49.5) 15 (15.2) 0.351 0.594
ERAP1-276 13 (30.2) 26 (60.5) 4 (9.3) 7 (35.0) 10 (50.0) 3 (15.0) 0.684 0.956
ERAP1-528 10 (23.8) 28 (66.7) 4 (9.5) 5 (25.0) 12 (60.0) 3 (15.0) 0.794 0.786
ERAP1-575 38 (88.4) 5 (11.6) 0 (0.0) 18 (90.0) 2 (10.0) 0 (0.0) 0.982 0.848
ERAP1-730 22 (35.5) 36 (58.1) 4 (6.5) 39 (39.0) 47 (47.0) 14 (14.0) 0.223 0.699
TAP1-333 27 (45.0) 25 (41.7) 8 (13.3) 53 (54.1) 29 (29.6) 16 (16.3) 0.299 0.611
TAP2-379 26 (60.5) 15 (34.9) 2 (4.7) 12 (63.2) 5 (26.3) 2 (10.5) 0.600 0.841
TAP2-651 41 (66.1) 3 (4.8) 18 (29.0) 35 (35.7) 1 (1.0) 62 (63.3) <0.001 <0.001
LMP2-60 24 (38.1) 35 (55.6) 4 (6.3) 35 (34.7) 50 (49.5) 16 (15.8) 0.195 0.217
LMP7-145 57 (93.4) 4 (6.6) 0 (0.0) 89 (89.9) 9 (9.1) 1 (1.0) 0.617 0.370
n (%) number (percentage)
All P values are corrected for multiple testing
Bold P values indicate statistical significance, i.e. P< 0.05
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In the Balinese population, no haplotype combinations
with a significant association with cancer risk could be
identified.
However, as shown in Table 9, in the Javanese population,
combined analysis of both haplotype blocks identified a spe-
cific combination consisting of the ERAP1-575 locus on chro-
mosome 5 and the TAP2-379 and TAP2-651markers on chro-
mosome 6 which had a significantly different distribution
among cases and controls (global P=0.008). Specifically, the
combination of a minor allele at ERAP1-575 with major al-
leles at both TAP2 loci was associatedwith an increased risk of
cervical cancer; the PAF for this haplotype was 3.9 %.
Discussion
The APM is considered to be a key factor in HLA class I
peptide presentation, which, in turn, mediates recognition
and lysis of transformed cells by cytotoxic T lymphocytes.
Alterations in the APM have been shown to be associatedwith
altered repertoires of peptides available for presentation, there-
by influencing the possibility and extent of T lymphocyte-
mediated immune reactions (Chang and Ferrone 2007; Falk
and Rotzschke 2002; Hammer et al. 2006; Saric et al. 2002;
Saveanu et al. 2005; Yan et al. 2006; York et al. 2002, 2006).
Moreover, multiple associations between tumour progression
Table 4 SNP allele distributions in the Javanese population
SNP Controls (n=210) n (%) Cases (n=196) n (%) OR (95 % CI) (minor vs. major allele) Allele distribution P value
Major allele Minor allele Major allele Minor allele
ERAP1-56 173 (84.8) 31 (15.2) 147 (78.2) 41 (21.8) 1.557 (0.929–2.607) 0.092
ERAP1-127 99 (49.5) 101 (50.5) 109 (59.9) 73 (40.1) 0.656 (0.437–0.985) 0.042
ERAP1-276 129 (61.4) 81 (38.6) 102 (56.7) 78 (43.3) 1.218 (0.812–1.826) 0.346
ERAP1-528 99 (48.5) 105 (51.5) 107 (59.4) 73 (40.6) 0.643 (0.429–0.964) 0.032
ERAP1-575 204 (98.1) 4 (1.9) 179 (94.2) 11 (5.8) 3.134 (0.981–10.016) 0.054
ERAP1-730 105 (50.5) 103 (49.5) 114 (61.3) 72 (38.7) 0.644 (0.431–0.962) 0.031
TAP1-333 136 (66.7) 68 (33.3) 123 (70.7) 51 (29.3) 0.829 (0.535–1.284) 0.408
TAP2-379 132 (65.3) 70 (34.7) 130 (71.4) 52 (28.6) 0.754 (0.489–1.163) 0.203
TAP2-651 201 (96.6) 7 (3.4) 189 (99.5) 1 (0.5) 0.152 (0.019–1.247) 0.077
LMP2-60 152 (73.8) 54 (26.2) 134 (72.8) 50 (27.2) 1.050 (0.670–1.646) 0.843
LMP7-145 186 (90.3) 20 (9.7) 177 (95.2) 9 (4.8) 0.473 (0.210–1.066) 0.071
n (%) number (percentage), OR odds ratio, 95 % CI 95 % confidence interval
All P values are corrected for multiple testing
Bold P values indicate statistical significance, i.e. P< 0.05
Table 5 SNP allele distributions in the Balinese population
SNP Controls (n=136) n (%) Cases (n=206) n (%) OR (95 % CI) (minor vs. major allele) Allele distribution P value
Major allele Minor allele Major allele Minor allele
ERAP1-56 70 (85.4) 12 (14.6) 27 (75.0) 9 (25.0) 1.944 (0.736–5.138) 0.181
ERAP1-127 78 (62.9) 46 (37.1) 119 (60.1) 79 (39.9) 1.126 (0.709–1.787) 0.627
ERAP1-276 52 (60.5) 34 (39.5) 24 (60.0) 16 (40.0) 1.020 (0.474–2.194) 0.963
ERAP1-528 48 (57.1) 36 (42.9) 22 (55.0) 18 (45.0) 1.091 (0.511–2.328) 0.833
ERAP1-575 81 (94.2) 5 (5.8) 38 (95.0) 2 (5.0) 0.853 (0.158–4.596) 0.863
ERAP1-730 80 (64.5) 44 (35.5) 125 (62.5) 75 (37.5) 1.091 (0.684–1.739) 0.560
TAP1-333 79 (65.8) 41 (34.2) 135 (68.9) 61 (31.1) 0.871 (0.537–1.412) 0.587
TAP2-379 67 (77.9) 19 (22.1) 29 (76.3) 9 (23.7) 1.094 (0.443–2.705) 0.856
TAP2-651 85 (68.5) 39 (31.5) 71 (36.2) 125 (63.8) 3.837 (2.379–6.189) <0.001
LMP2-60 83 (65.9) 43 (34.1) 120 (59.4) 82 (40.6) 1.319 (0.830–2.096) 0.244
LMP7-145 118 (96.7) 4 (3.3) 187 (94.4) 11 (5.6) 1.735 (0.540–5.576) 0.361
n (%)=n (%) number (percentage), OR odds ratio, 95 % CI 95 % confidence interval
All P values are corrected for multiple testing
Bold P values indicate statistical significance, i.e. P< 0.05
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and APM component defects have been described. In partic-
ular, we have previously shown that downregulation of TAP1,
LMP7 and ERAP1 expression is associated with decreased
survival in HPV-mediated cervical carcinoma in Dutch pa-
tients (Mehta et al. 2008).
A growing body of evidence is emerging pointing towards
a genetic predisposition to HPV-mediated malignant transfor-
mation. Genetic variation in two APM SNPs has been
associated with HPV-associated esophageal carcinoma (Cao
et al. 2005). Furthermore, we have previously demonstrated
that genetic variation in the genes encoding TAP2, LMP7 and
ERAP1 is significantly associated with increased risk of de-
veloping cervical carcinoma and with poor prognosis among
cervical carcinoma patients and that the effect of specific com-
binations of SNPs is cumulative as compared to the individual
SNPs (Mehta et al. 2007, 2009). These data were limited to a
Table 6 Estimated haplotype frequencies based on all SNPs and tests for distributions among cases and controls in the Javanese population
Chromosome Haplotype
ID




5a H1 G–C–T–T–C–G 82 (42.0) 51 (31.9) 0.65 (0.42–1.00) 0.051 0.162
H2 G–G–C–C–C–C 70 (35.5) 57 (35.6) 1.01 (0.65–1.55) 0.968
H3 A–G–T–C–C–C 12 (6.2) 18 (11.3) 1.93 (0.90–4.13) 0.090
H4 A–C–T–T–C–G 11 (5.4) 12 (7.5) 1.43 (0.61–3.37) 0.420
H5 A–G–C–C–C–C 7 (3.7) 9 (5.6) 1.54 (0.57–4.17) 0.402
H6 G–C–T–T–C–C 5 (2.6) 2 (1.3) 0.49 (0.09–2.53) 0.409
H7 G–G–T–C–T–C 3 (1.5) 8 (5.0) 3.39 (0.88–13.01) 0.075
H8 G–C–T–C–C–C 2 (1.0) 2 (1.3) 1.2 (0.17–8.50) 0.865
6b H1 G–C–G–A–G 49 (24.7) 54 (33.5) 1.54 (0.97–2.43) 0.065 0.331
H2 G–C–G–G–G 45 (22.5) 35 (21.3) 0.93 (0.57–1.54) 0.787
H3 A–C–G–A–A 34 (17.1) 26 (16.1) 0.93 (0.54–1.63) 0.809
H4 G–A–G–A–G 17 (8.6) 8 (4.8) 0.53 (0.22–1.28) 0.158
H5 G–C–G–G–A 17 (8.5) 11 (6.9) 0.79 (0.36–1.73) 0.568
H6 G–C–G–A–A 13 (6.6) 8 (5.0) 0.75 (0.30–1.84) 0.545
H7 A–C–G–A–G 12 (6.2) 16 (10.1) 1.71 (0.79–3.68) 0.172
H8 G–C–A–A–G 3 (1.7) 1 (0.6) 0.37 (0.04–3.45) 0.389
H9 A–C–G–G–A 3 (1.4) 2 (0.9) 0.63 (0.09–4.61) 0.658
a Chromosome 5 haplotype sequences listed in following order: ERAP1-56–ERAP1-127–ERAP1-276–ERAP1-528–ERAP1-575–ERAP1-730
b Chromosome 6 haplotype sequences listed in following order: LMP2-60–LMP7-145–TAP2-651–TAP1-333–TAP2-379
All P values are corrected for multiple testing
Table 7 Estimated haplotype frequencies based on all SNPs and tests for distributions among cases and controls in the Balinese population
Chromosome Haplotype ID Haplotype sequence Controls (n=136) n (%) Cases (n=206)
n (%)




5a H1 G–C–T–C–C–G 30 (39.5) 11 (32.4) 0.73 (0.31–1.72) 0.481 0.848
H2 G–G–C–T–C–C 27 (35.5) 11 (32.4) 0.87 (0.37–2.05) 0.763
H3 A–G–T–T–C–C 7 (9.2) 4 (11.8) 1.31 (0.36–4.83) 0.697
H4 G–G–T–T–T–C 5 (6.6) 2 (5.9) 0.89 (0.16–4.82) 0.902
H5 A–G–C–T–C–C 3 (3.9) 3 (8.8) 2.35 (0.45–12.32) 0.316
H6 A–C–T–C–C–G 2 (2.6) 1 (2.9) 1.12 (0.10–12.80) 0.933
6b H1 A–G–C–G–C 25 (32.5) 7 (21.6) 0.57 (0.21–1.54) 0.272 0.472
H2 G–G–C–G–C 20 (26.2) 6 (21.4) 0.77 (0.28–2.10) 0.624
H3 A–G–C–A–C 13 (16.4) 6 (20.4) 1.31 (0.45–3.81) 0.633
H4 A–A–C–A–C 11 (14.4) 7 (23.0) 1.77 (0.61–5.09) 0.295
H5 A–G–C–G–A 2 (3.0) 2 (6.7) 2.35 (0.34–16.41) 0.395
a Chromosome 5 haplotype sequences listed in following order: ERAP1-56–ERAP1-127–ERAP1-276–ERAP1-528–ERAP1-575–ERAP1-730
b Chromosome 6 haplotype sequences listed in following order: LMP2-60–LMP7-145–TAP2-651–TAP1-333–TAP2-379
All P values are corrected for multiple testing
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relatively homogeneous Dutch population; evidence regard-
ing such associations in other heterogeneous populations is
scarce.
Therefore, in the present study, we have investigated the
association between 11 previously documented, non-
synonymous SNPs in seven genes encoding different APM
components and cervical carcinoma risk in two distinct Indo-
nesian populations. Our results show that genotype and allele
distributions at various loci are significantly associated with
occurrence of cervical carcinoma but that patterns of associa-
tion differ greatly between the two populations. Specifically,
in the Javanese population, a combination of the ERAP1-575
locus on chromosome 5 and the TAP2-379 and TAP2-651
markers on chromosome 6 was significantly associated with
cervical carcinoma risk, whereas in the Balinese population,
only the TAP2-651 locus exhibited this association.
The findings in the Javanese population underline the role
of genetic variation at the ERAP1 and TAP2 loci in cervical
carcinoma as previously described by us (Mehta et al. 2007,
2009). Genetic variation at these loci may cause functional
alterations in the associated proteins, e.g. TAP transport effi-
ciency and ERAP1 proteolytic activity. Additionally, structur-
al stability of the associated mRNA and protein may be affect-
ed by these SNPs. Ultimately, these changes may lead to var-
iation in the repertoire of HPV-derived peptides available for
HLA class I-mediated presentation, thereby affecting immune
evasion of HPV-transformed cells. However, to date, there is
no conclusive evidence regarding the functional and/or struc-
tural consequences of genetic variation at these loci.
As stated previously, the observed associations between
APM SNPs and cervical carcinoma may not be caused by
the investigated loci at all but may reflect effects of other loci
in linkage disequilibrium with the SNPs in the present study.
However, to our knowledge, there is no data concerning other
chromosome 5 or 6 loci in relation to cervical carcinoma risk.
Moreover, the pattern we have described here and in our pre-
vious studies, i.e. that unlinked loci on different chromosomes
interact in a contribution to change susceptibility to disease, is
in keeping with similar findings in other vertebrates, where it
has been suggested that variation in the APM pathways may
be more important than variation in the major histocompati-
bility complex (MHC) itself in the attenuation of immune
responses (Kaufman 2013).
The striking differences in patterns of association of genetic
variation in the Javanese and Balinese populations may be
caused by several mechanisms. Historically, Bali was a rela-
tively isolated region of Indonesia with therefore a more ho-
mogeneous genepool. In contrast, Java has been subject to
extensive migration and has a more heterogeneous genetic
composition (Chow et al. 2005; Shepard et al. 2005).
Table 8 Chromosome 5 and 6 significant haplotype permutations in the Javanese population
Haplotype sequence Controls (n=210) n (%) Cases (n=196) n (%) OR (95 % CI) Haplotype-specific P value Global P value
Chromosome 5
ERAP1-575–ERAP1-730
C–G 102 (49.0) 72 (39.1) 0.67 (0.45–1.00) 0.049 0.014
C–C 102 (49.0) 101 (54.9) 1.26 (0.85–1.88) 0.257
T–C 3 (1.4) 11 (6.0) 4.35 (1.18–15.86) 0.026
Chromosome 6
TAP2-379–TAP2-651
A–G 19 (9.2) 9 (4.9) 0.51 (0.22–1.15) 0.110 0.042
C–G 180 (87.4) 174 (94.6) 2.50 (1.17–5.35) 0.018
C–A 6 (2.9) 1 (0.5) 0.18 (0.02–1.55) 0.122
All P values are corrected for multiple testing
Bold P values indicate statistical significance, i.e. P< 0.05
Table 9 Haplotype interaction analysis in the Javanese population
Haplotype sequence Controls (n=210) n (%) Cases (n=196) n (%) OR (95 % CI) Haplotype-specific P value Global P value
ERAP1-575–TAP2-379–TAP2-651
C–A–G 19 (9.0) 8 (4.4) 0.47 (0.20–1.09) 0.081 0.008
C–C–G 177 (85.9) 162 (89.0) 1.33 (0.72–1.44) 0.366
C–C–A 5 (2.4) 1 (0.5) 0.22 (0.03–1.92) 0.154
T–C–G 4 (1.7) 10 (5.5) 3.36 (0.98–11.56) 0.054
All P values are corrected for multiple testing
Bold P values indicate statistical significance, i.e. P< 0.05
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Moreover, our group has previously shown that the distribu-
tion of oncogenic HPV subtypes differs greatly amongst these
Indonesian regions (Vet et al. 2008). Therefore, differences in
the genetic variation patterns in these regions in relation to
cervical carcinoma occurrence may reflect a combination of
different genetic composition and differences in HPV subtype
distribution. This leads to the hypothesis that different HPV
subtypes may exploit different host genetic factors to evade
the immune system and establish malignant transformation.
This may also explain the difference in association patterns
in the current study as compared to the Dutch population,
which we have described previously (Mehta et al. 2007).
Moreover, the genetic homogeneity of the Balinese popula-
tion may explain why a single locus exhibits such a strong
association with cervical carcinoma risk as opposed to a com-
bination of loci in the genetically heterogeneous Javanese
population.
In conclusion, we report the systematic analysis of several
SNPs in genes encoding APM components in cervical carci-
noma in two distinct Indonesian populations. In this analysis,
we utilize a previously described robust and comprehensive
statistical method for evaluation of multimarker effects and of
haplotype interactions. We demonstrate a significant associa-
tion between genetic variation in specific combinations of
these SNPs and cervical carcinoma risk and, more important-
ly, that these association patterns differ between the two pop-
ulations.We hypothesize that these differences reflect not only
different genetic compositions of the populations but also
well-documented differences in HPV subtype distributions.
This insight, combined with ongoing understanding of the
relevance of APM component SNPs in HPV-mediated cervi-
cal carcinogenesis, may be an important determinant in design
and effectiveness of HPV-targeted vaccines and immunother-
apeutic regimens.
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